Obstetrics, gynecology and reproductive medicine guidelines

Obesity, eating disorders

PubMed Free Full Text

Obesity: pharmacologic treatment

 

Australia

• Australian Family Physician
  • Pharmacotherapy for obesity [2017]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Pharmacoeconomic Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • Clinical Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • CADTH Canadian Drug Expert Committee Recommendation: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave — Bausch Health, Canada Inc.) [2020]

Europe

• European Association for the Study of Obesity
  • 2014 EASO Position Statement on the Use of Anti-Obesity Drugs [2015]

• European Medicines Agency
  • Guideline on clinical evaluation of medicinal products used in weight management [2016]

International

• BMC Medicine
  • Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review [2016]

Saudi Arabia

• Scientific World Journal
  • Safety Evaluation of Local Weight-Gain Formulas in the Saudi Arabian Markets [2015]

United Kingdom

• National Institute for Health and Care Excellence
  • Liraglutide for managing overweight and obesity [2020]
  • Obese, overweight with risk factors: liraglutide (Saxenda) [2017]
  • Naltrexone–bupropion for managing overweight and obesity [2017]

United States of America

• Endocrine Practice
  • Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015–2018 [2021]

• Endocrine Society
  • Pharmacological management of obesity: an Endocrine Society clinical practice guideline [2015]

• Obesity
  • Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010 [2015]

{Related topics}

• Guidelines
  • Obesity